PreveCeutical Announces Chief Financial Officer Shabira Rajan, CPA, CGA

VANCOUVER, British Columbia, Sept. 06, 2016 (GLOBE NEWSWIRE) — PreveCeutical Medical Inc. (“PreveCeutical”, or the “Company”), a health and wellness company focused on utilizing nature and science for the benefit of health conscious consumers, announces the appointment of Ms. Shabira Rajan, CPA, CGA as Chief Financial Officer following the resignation of Jeremy Wright, CPA, CMA.  Mr. Wright will continue as a Director of the Company.

Ms. Rajan has an extensive professional history, including her most recent positions as the Director of Finance at the Canadian Freestyle Ski Association, owner of SHROFF Financial Management, and Director of Finance for Canada Line Rapid Transit Inc., a major ($2 billion), complex, P3 infrastructure project.

Ms. Rajan is a Certified Professional Accountant (Certified General Accountant), holds an MBA and an Advanced Specialty Certificate in Forensic Science Technology, Forensic, and Investigative Accounting Option.  She was a Project Management Professional and an associate member of the Institute of Chartered Secretaries and Administrators.  She recently completed the Executive Leadership – Developing Sustainable Nonprofit Organizations in the 21st Century program with the City University of Seattle. Ms. Rajan has served as a board member with WAVAW and was the Chair, Education and Recruiting with the Richmond/South Delta Chapter of CGA-BC.

Mr. Wright, CPA, CMA has been an instrumental member of our team as Chief Financial Officer and Director.  As we complete our application to the Canadian Securities Exchange, Mr. Wright has resigned as Chief Financial Officer, and will remain as a Director of the Company transitioning day-to-day activities to Ms. Rajan.

“We are very excited to further strengthen our team with the addition with Shabira.  She brings an incredible breadth of experience to our Company, and we’re looking forward to her leadership of our finance Unit,” said Stephen Van Deventer, Chairman, and CEO at PreveCeutical. “We are very appreciative for Jeremy’s efforts.  His input and financial background have been incredibly valuable, and we look forward to his continued support as a Director of the Company going forward.”

About PreveCeutical

For more information about PreveCeutical, please visit www.preveceutical.com, follow us on Twitter: https://twitter.com/preveceuticals, or on Facebook: www.facebook.com/Preveceutical

On Behalf of the Board,

Stephen Van Deventer

Chairman & CEO

This news release may contain forward-looking statements, including without limitation, future operations of PreveCeutical Medical Inc. (the “Company”). Forward-looking statements address future events and conditions and therefore involve inherent risks, uncertainties and assumptions. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can be identified by the use of forwarding-looking wording such as “may,” “expect,” “estimate,” “will,” “anticipate,” “intend,” “believe” and “continue” or the negative thereof or similar variations.  Actual results may differ materially from those currently anticipated in such statements, and the Company undertakes no obligation to update such statements, except as required by law.  While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks. In particular, there is no guarantee that the Blue Scorpion Venom will effectively treat or cure cancer or other diseases. Accordingly, actual results may differ materially from those currently anticipated in such statements.

The Company has made numerous assumptions regarding, among other things: the effectiveness of its products; the demand for its products and the stability of economic and market conditions. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including that the Company may lose or abandon or may fail to receive necessary licenses and permits; labour disputes; the Company may not receive the necessary regulatory approvals for its products; the increase in cost estimates and the potential for unexpected costs and expenses; general economic and market conditions may worsen; market shifts may require a change in strategic focus; the Company may not be able to raise additional funds when necessary; litigation; and competition. Factors that could cause actual results to differ materially from those in forward-looking statements include the continued availability of capital and financing and general economic, market or business conditions, consumer sentiment towards the Company’s products, competition, the failure of counterparties to perform their contractual obligations, and fees charged by service providers.

All forward-looking statements concerning the Company’s plans and operations, including management’s assessment of the Company’s operational expectations or beliefs, may be subject to certain assumptions, risks, and uncertainties beyond the Company’s control. Investors are cautioned that any such statements are not guarantees of future performance and that actual performance and financial results may differ materially from any estimates or projections. Accordingly, readers should not place undue reliance on forward-looking statements and information, which are qualified in their entirety by this cautionary statement. There can be no assurance that forward-looking information, or the material factors or assumptions used to develop such forward-looking information, will prove to be accurate.

CONTACT: PreveCeutical Medical Inc.
Suite 605 – 815 Hornby Street,
Vancouver, B.C., V6Z 2E6, Canada
www.preveceutical.com
1 (866) 398-1288